Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
50-36-2
Molecular formula
C17H21NO4
Molecular weight
303.35 g/mol
Drug class
Ester-type local anaestheticsodium-channel blocker with sympathomimetic activity
Mechanism of action
Blocks voltage-gated sodium channels in neuronal membranes, inhibiting initiation and conduction of nerve impulses and producing local anaesthesia. Cocaine also inhibits catecholamine reuptake and causes local vasoconstriction; these additional effects contribute to cardiovascular and abuse risks.
Indications / reported uses
For the specific FDA-approved intranasal cocaine hydrochloride product (GOPRELTO): induction of local anaesthesia of nasal mucous membranes during diagnostic procedures and surgeries on or through the nasal cavities in adults. This is not a general systemic analgesic indication.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Cocaine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Cocaine Permitted Daily Exposure (PDE) report (the Cocaine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Cocaine Occupational Exposure Limit (OEL) report (the Cocaine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.